Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARALLAX: rhPTH(1-84) BID vs QD in Hypoparathyroidism
NCT02781844Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2017
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of parathyroid hormone 1-84 in hypoparathyroidism (4 cohorts), sponsored by Takeda. Primary endpoints: Time of Maximum Observed Concentration, Maximum Plasma Concentration and 12 more. Started Apr 2017; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT02781844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781844.